Abstract Glucagon-like peptide (GLP)-1 is an incretin hormone exhibiting several
pharmacological actions such as neuroprotection, increased cognitive function, cardio …

Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2
diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide …

Abstract Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control
through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …

Type 2 diabetes mellitus is a major and growing health problem throughout the world.
Current treatment approaches include diet, exercise, and a variety of pharmacological …

Glucagon‐like peptide‐1 (GLP‐1), a gut‐derived hormone secreted in response to nutrients,
has several glucose and weight regulating actions including enhancement of glucose …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …